Sawicka Emilia, Mirończuk Anna, Wojtukiewicz Marek Z, Sierko Ewa
Scientific Students Association affiliated with the Department of Oncology, Medical University of Bialystok, Poland.
Department of Oncology, Medical University of Bialystok, Poland; Comprehensive Cancer Center, Bialystok, Poland.
Contemp Oncol (Pozn). 2016;20(2):102-8. doi: 10.5114/wo.2016.60066. Epub 2016 Jun 14.
Operable pancreatic cancer is characterized by a high risk of recurrence. Efforts are made to incorporate new therapies. Throughout the world there is a lack of uniform recommendations concerning the adjuvant treatment of pancreatic cancer patients, due to confusing evidence-based data. The patients recruited to clinical trials differ from the population of patients treated in everyday practice. These differences have an influence on tolerance of treatment, toxicity and results of therapy. The decision on administration of adjuvant treatment is made individually and differs from center to center. A review of the literature concerning both results and tolerance of postoperative chemoradiotherapy of pancreatic cancer patients is presented.
可手术切除的胰腺癌具有高复发风险。人们致力于纳入新的治疗方法。由于循证数据令人困惑，全球对于胰腺癌患者的辅助治疗缺乏统一的建议。参加临床试验的患者与日常临床治疗的患者群体有所不同。这些差异对治疗耐受性、毒性和治疗结果均有影响。辅助治疗的决策是个体化的，且各中心之间存在差异。本文对有关胰腺癌患者术后放化疗的结果及耐受性的文献进行了综述。
